| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 66.97 mm | 66.97 mm | 66.97 mm | 66.97 mm | 66.97 mm | 66.97 mm |
| Cash burn (monthly) | 14.80 mm | (no burn) | 7.39 mm | 6.32 mm | 5.19 mm | 5.84 mm |
| Cash used (since last report) | 36.51 mm | n/a | 18.24 mm | 15.59 mm | 12.80 mm | 14.41 mm |
| Cash remaining | 30.46 mm | n/a | 48.73 mm | 51.38 mm | 54.17 mm | 52.56 mm |
| Runway (months of cash) | 2.1 | n/a | 6.6 | 8.1 | 10.4 | 9.0 |
| 13F holders | Current |
|---|---|
| Total holders | 86 |
| Opened positions | 23 |
| Closed positions | 3 |
| Increased positions | 22 |
| Reduced positions | 22 |
| 13F shares | Current |
|---|---|
| Total value | 580.13 bn |
| Total shares | 13.85 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| BlackRock | 1.37 mm | $57.56 bn |
| EcoR1 Capital | 1.27 mm | $53.35 bn |
| Samsara BioCapital | 1.27 mm | $53.20 bn |
| RTW Investments | 1.14 mm | $47.64 bn |
| Great Point Partners | 1.00 mm | $42.14 bn |
| Redmile | 964.35 k | $40.46 bn |
| FMR | 731.80 k | $30.71 bn |
| JHG Janus Henderson | 709.47 k | $29.78 bn |
| Vanguard | 576.16 k | $24.18 bn |
| Casdin Capital | 524.62 k | $22.01 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 Nov 24 | Samsara BioCapital GP | Common Stock | Buy | Acquire P | Yes | No | 27.5 | 2,000 | 55.00 k | 1,717,127 |
| 26 Nov 24 | Samsara BioCapital GP | Common Stock | Buy | Acquire P | Yes | No | 26.73 | 15,219 | 406.80 k | 1,715,127 |
| 26 Nov 24 | Samsara BioCapital GP | Common Stock | Buy | Acquire P | Yes | No | 26.01 | 10,803 | 280.99 k | 1,699,908 |
| 26 Nov 24 | Samsara BioCapital GP | Common Stock | Buy | Acquire P | Yes | No | 24.91 | 20,748 | 516.83 k | 1,689,105 |
| 22 Nov 24 | Christine Mikail Cvijic | Common Stock | Buy | Acquire P | No | No | 20.475 | 24,000 | 491.40 k | 76,844 |
| 22 Nov 24 | Rachel McMinn | Common Stock | Buy | Acquire P | No | No | 20.4 | 47,500 | 969.00 k | 1,297,859 |
| 14 Jun 24 | Noonberg Sarah B. | Stock Option Common Stock | Grant | Acquire A | No | No | 42.59 | 7,700 | 327.94 k | 7,700 |
